Are you that kind of person who celebrates milestones of your life with getting a tattoo? These milestones could be anything, including the things you achieved, or the things you could not achieve but taught you a lesson. If you are this person, then you must have wondered if you can donate blood with all the tattoos on your body? There are lots of rumors on how can one donate blood, or if at all they are allowed to donate blood. So let's get into its nitty gritty!

As per American Red Cross, in most states, a tattoo is acceptable if the tattoo was applied by a state-regulated entity. Which means the tattoo artist must be licensed and must practice following all the guidelines, using sterile needles and ink that is not reused. The same is the guideline for cosmetic tattoos, which includes microblading of eyebrows. If it is done by a licensed artist in a regulated state, then it is acceptable.

However, if you got your tattoo in a state that does not regulate tattoo facilities, you must wait three months after it was applied.

The states that do not regulate tattoo facilities are:

• Arizona
• District of Columbia
• Georgia
• Idaho
• Maryland
• Massachusetts
• Nevada
• New Hampshire
• New York
• Pennsylvania
• Utah
• Wyoming

Body Piercing

Similar is the case with body piercings. It has to be done following the regulation, here the key is that the instrument used has to be a single-use equipment and disposable. Which means if you are getting it by a gun, or an earring cassette, they have to be disposable. In case you got your piercing with a reusable gun or a reusable instrument, you will be required to wait for three months.

Three-Month Wait Period

The reason behind the wait time is associated with the concerns of hepatitis, which could be easily transmitted from donors to patients through transfusion. All blood donations are thus tested for hepatitis B and hepatitis C, with several tests. However, not always are these tests are perfect, thus the three-month period is given.

What Dangers Loom Over?

Donating blood after getting a tattoo can be dangerous as unclean tattoo needle could carry bloodborne viruses, which are hepatitis B, hepatitis C and HIV. In 2020, the Food and Drug Administration (FDA) updated its guideline, making the wait time shorter from one year to three months. This is because if you contract a bloodborne illness, it could be detectable within the period of 3 months.

What else makes you ineligible to donate blood?

There are other reasons why you may not be allowed to donate blood. As per the American Red Cross, you are not allowed to donate blood if you have

• hepatitis B or C
• HIV
• Chagas disease, which is a parasitic infection that kissing bugs cause
• leishmaniasis, a parasitic infection that sand flies cause
• Cruetzfeldt-Jakob Disease (CJD), a rare disorder that leads to mental deterioration
• Ebola virus
• hemochromatosis, which means extreme build up of iron
• hemophilia
• jaundice
• sickle cell disease

As per the National Institutes of Health (NIH) Blood Bank, these conditions make you permanently ineligible from donating blood.

While there are certain conditions that makes your permanently ineligible, there are other conditions that makes you temporarily ineligible from donating blood. These include:

• If you have a bleeding condition, and have issues with your blood clotting
• If you have received transfusion from a person
• If you have cancer. Here, the eligibility depend son the type of cancer you have
• If you have recently underwent a dental or oral surgery. In such a case, you would have to wait for three days
• If you had a recent heart attack, heart surgery or angina. You must wait for 6 months
• If you are pregnant, you can only donate blood after 6 months after delivering your child

When patients first hear the term "bone marrow transplant," they often picture a complex surgery involving the bones or spine. This is perhaps the most persistent misconception surrounding one of modern medicine's most remarkable achievements.

Unlike other organ transplants (kidney/ heart/ liver, etc), a bone marrow transplant is not a surgery at all! It is administered much like a blood transfusion, through a simple intravenous line. Yet this deceptively simple procedure can rebuild an entire blood-forming and immune system from scratch, offering a genuine cure for blood cancers and other serious blood disorders.

Bone marrow is the body's blood factory, producing the red cells that carry oxygen, the white cells that fight infection, and the platelets that prevent bleeding. At its heart lie blood-forming stem cells or the "parent cells" capable of generating every blood cell the body will ever need.

In leukemia and related cancers, these stem cells turn rogue, crowding out healthy ones. In several inherited disorders, the marrow simply fails to manufacture healthy cells at all. A transplant addresses the problem at its root, replacing defective stem cells with healthy ones.

I often explain this to patients using the language of farming. Before sowing fresh seed, a farmer clears the field of weeds. Similarly, before healthy stem cells can be transplanted, doctors must prepare the marrow through chemotherapy and, in select cases, radiation, a stage called conditioning. Once this was punishingly intensive, limiting transplants to the young and fit. Today, reduced-intensity regimens, which are carefully tailored to suit even the old or frail patients, have extended this option to older adults and those with other health conditions.

The transplant itself is almost anticlimactic in its simplicity: stem cells are infused through an IV, with no incision or operating theatre required. These cells possess a natural ability doctors call "homing": they find their own way into the bone marrow and settle there. Over two to four weeks, they begin producing healthy blood, a process called engraftment.

For decades, the greatest obstacle to transplantation was finding a matched donor. Traditionally, only a fully matched sibling would do, leaving many patients, particularly in a genetically diverse country like India, without options. That has changed decisively. Half-matched family transplants and unrelated donors identified through registries now succeed at rates that rival matched-sibling transplants. Nearly every patient today has a realistic path to a suitable donor.

Technology is reshaping this field further. Gene therapy is opening a new chapter for disorders such as sickle cell disease and thalassemia, correcting a patient's own stem cells in the laboratory rather than relying on a donor, though such therapies remain costly and available only in select countries for now.

Recovery, however, is a marathon, not a sprint. It can take months as the immune system rebuilds, requiring vigilant monitoring for infection and for graft-versus-host disease, in which transplanted immune cells attack the patient's own tissues. Advances in immunosuppressive and targeted therapies have greatly improved our ability to manage this complication, allowing most survivors to gradually return to work, education and family life.

A blood cancer diagnosis remains frightening, but treatment has advanced tremendously in two decades. Bone marrow transplantation is no longer experimental or exceptionally hazardous: it is established, evidence-based, and growing safer and more accessible across India.

Its truest achievement is not simply extending life, but restoring it: another birthday, another child watched growing up, another future reclaimed. For these patients, a transplant is quite literally a chance to begin again.

(Dr. Narendra Agrawal, Hematologist and Bone Marrow Transplant Physician and Senior Consultant and Unit Head of Haemato-Oncology at Rajiv Gandhi Cancer Institute & Research Centre.)

A six-in-one (hexavalent) vaccine could make India's Universal Immunization Program more efficient, convenient for families, and cost-effective if it becomes widely available at an affordable price, according to a study led by the Ministry of Health and Family Welfare.

The study found that while the hexavalent vaccine has higher upfront procurement costs, it could reduce the number of injections, improve operational efficiency, lower healthcare workload, and save time for caregivers.

What Is the 6-in-1 Vaccine?

The hexavalent vaccine protects children against six diseases with a single injection:

• Diphtheria
• Tetanus
• Pertussis (whooping cough)
• Hepatitis B
• Hemophilus influenzae type b (Hib)
• Polio

Combining multiple vaccines into one shot reduces the number of injections infants receive during routine immunization visits.

Key Findings

Also read: India Records 20,138 Organ Transplants In 2025; Deceased Donor Transplants Reach 3,526

Researchers found that the vaccine's price is the biggest factor determining the overall cost of introducing it into India's immunization program.

The study estimated that:

• A 50% reduction in the vaccine price would allow operational savings to outweigh the additional vaccine procurement costs under the primary immunization schedule.
• Lower vaccine prices could also make broader implementation, including booster doses, economically beneficial.

The findings were published in the peer-reviewed journal Human Vaccines & Immunotherapeutics.

Potential Benefits of the 6-in-1 Vaccine

According to the study, introducing the hexavalent vaccine could:

• Reduce the number of injections for infants.
• Make immunization visits more convenient for children and caregivers.
• Lower cold-chain storage requirements
• Reduce the use of syringes and other vaccination supplies.
• Save time for Auxiliary Nurse Midwives (ANMs) during vaccine administration and record-keeping
• Reduce the workload of cold-chain handlers and vaccine managers.
• Save time for parents and caregivers during vaccination visits.

India's Current Immunization Program

Read More: India's National Hepatitis Program Screens Over 210.6 Million, Treats 612,000 Patients

India runs one of the world's largest immunization programs, vaccinating nearly 26 million babies every year.

The program protects children against 12 vaccine-preventable diseases, including:

• Diphtheria
• Pertussis
• Tetanus
• Polio
• Measles
• Rubella
• Tuberculosis
• Hepatitis B
• Hib-related meningitis and pneumonia
• Rotavirus diarrhea
• Pneumococcal pneumonia
• Japanese encephalitis (in endemic districts)

What the Study Evaluated

A team of researchers, including from The George Institute for Global Health India, The Gates Foundation, and Gavi, The Vaccine Alliance, assessed two implementation scenarios:

• Replacing the current pentavalent vaccine and fractional inactivated polio vaccine (fIPV) with the hexavalent vaccine during the primary immunization schedule.
• Replacing both the primary schedule and the DTP booster dose with the hexavalent vaccine.

The analysis considered costs from both government and household perspectives, including:

• Vaccine procurement
• Syringes and vaccination supplies
• Cold-chain logistics
• Healthcare worker time
• Caregiver time

The researchers noted that replacing the current pentavalent, fIPV and DTP booster vaccines with the hexavalent vaccine would initially increase vaccine procurement costs. However, these would be partially offset by savings from:

• Lower vaccine delivery costs
• Reduced syringe use
• Lower cold-chain requirements
• Time savings for healthcare workers involved in procurement, storage and vaccine administration

The team added that based on previous vaccine procurement trends, a 50% reduction in the hexavalent vaccine price would make the switch economically favorable under the primary immunization schedule. Further price reductions could also generate cost savings for the booster-dose scenario.

"Our study demonstrates that although the hexavalent vaccine carries a higher upfront procurement cost, it also generates important efficiencies by reducing injections, easing pressure on frontline health workers, lowering cold-chain requirements and saving caregivers' time. These findings provide important economic evidence that can inform future policy discussions on strengthening India's immunization program," Dr. Susmita said.

Blockbuster GLP-1 drugs, with semaglutide as the key ingredient, have shown promise in treating conditions ranging from diabetes and obesity to certain cancers.

Now, US researchers are set to test whether semaglutide can also help treat alcohol use disorder (AUD), particularly among veterans. AUD affects an estimated 400 million people worldwide, or about 7% of people aged 15 years and older.

The US Department of Veterans Affairs (VA) has announced a new clinical trial to evaluate the effectiveness of semaglutide in treating AUD and is aimed directly at benefiting Veterans.

"By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery," said VA Secretary Doug Collins.

Currently, more than 400,000 US veterans have been diagnosed with AUD, while an estimated 11% of US adults are affected by the condition.

What Does the Trial Aim to Find?

Also read: GLP-1 Weight-Loss Drugs Show Promise for 17 Million With Binge Eating Disorder, Suggests Study

The study, called the Cessation or Reduction of Alcohol Consumption in Veterans (CRACV) trial, will enroll more than 600 veterans across 18 VA medical centers in the US.

Participants aged 18 to 80 with moderate or severe AUD will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety follow-up period.

Researchers will assess changes in alcohol consumption, overall health, and quality of life to determine whether semaglutide could become a new treatment option for alcohol use disorder.

Oral Semaglutide May Help Reduce Heavy Drinking

Evidence is also emerging that GLP-1 medications may influence alcohol consumption. A Phase 2 clinical trial published in the American Journal of Psychiatry in July suggests that oral semaglutide may help reduce heavy and harmful drinking, even among people who are not trying to quit alcohol completely.

The trial included 50 adults with moderate to severe alcohol use disorder who wanted to reduce or stop drinking. Participants were randomly assigned to receive either daily oral semaglutide or a placebo for eight weeks.

The semaglutide dose increased from 3 mg per day during the first four weeks to 7 mg per day during the remaining four weeks.

Read More: GLP-1 Microdosing: People Are Experimenting With Weight Loss Drugs & What Do Experts Have To Say About It?

While semaglutide did not significantly reduce laboratory-assessed craving or the average number of drinks per day compared with placebo, it significantly reduced heavy drinking days.

Compared with participants receiving placebo, those taking semaglutide had fewer heavy drinking days during the final four weeks of treatment. They also consumed fewer drinks on drinking days and reported greater reductions in everyday alcohol cravings and alcohol-related negative consequences.

"It could represent a new treatment option for alcohol use disorder, particularly for those who have not benefited from existing medications, and may reduce alcohol-related health and social harms. Importantly, even reducing heavy drinking can lead to meaningful improvements for patients and families," said Joseph Schacht, PhD, professor of psychiatry at the University of Colorado Anschutz School of Medicine.